%PDF-1.2
%
1 0 obj
<<
/CreationDate (D:20050926093503+02'00')
/ModDate (D:20050926093503+02'00')
/Producer (Acrobat Distiller 5.0.5 \(Macintosh\))
/Title (Carta FM 2)
/Creator (QuarkXPress\(tm\) 4.1)
>>
endobj
2 0 obj
<<
/Type /Metadata
/Subtype /XML
/Length 949
>>
stream
Carta FM 2
endstream
endobj
4 0 obj
<<
/Length 4973
>>
stream
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
0 0 0 0 k
/GS1 gs
26.77 691.61 490.35 -634.96 re
f
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
26.77 719.95 m
517.12 719.95 l
S
26.77 788 490.35 -56 re
f
26.77 48 24.01 -17.01 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
10 0 0 10 26.7705 33.1601 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(62)Tj
ET
0 0 0 0 k
26.77 529.78 490.35 -367.13 re
f
BT
11 0 0 11 37.5138 514.9843 Tm
0 0 0 1 k
-0.0002 Tc
0.0001 Tw
[(Sr)54.7(. Director:)]TJ
0 -2.3636 TD
-0.0001 Tc
0.0251 Tw
(Los doctores Andreu Martnez FJ y Martnez Ma-)Tj
-0.9767 -1.1818 TD
0.0027 Tc
0.1223 Tw
(teu JM han presentado recientemente en su revista)Tj
T*
0.0056 Tc
0.1194 Tw
(un caso de sarcoma de Kaposi epidmico larngeo)Tj
T*
0 Tc
0.0515 Tw
(en un paciente afecto de infeccin por el virus de la)Tj
T*
-0.0001 Tc
0.0001 Tw
(inmunodeficiencia humana \(VIH\))Tj
6.6 0 0 6.6 175.8076 440.6143 Tm
0 Tc
0 Tw
(1)Tj
11 0 0 11 179.1076 436.9843 Tm
(. )Tj
-12.8722 -1.1818 TD
0.0289 Tw
(El caso es muy interesante, pero en la descripcin)Tj
-0.9767 -1.1818 TD
0.0204 Tc
0.1046 Tw
(del tratamiento antirretroviral se refieren algunas)Tj
T*
0 Tc
0 Tw
[(inexactitudes que me parece adecuado comentar)54.9(.)]TJ
0.9767 -1.1818 TD
0.0154 Tw
(Indica que se inici tratamiento antirretroviral uti-)Tj
-0.9767 -1.1818 TD
0.0039 Tc
0.1211 Tw
(lizando dos inhibidores de la transcriptasa inversa,)Tj
T*
0 Tc
0.0013 Tw
(zidovudina y lamivudina y un inhibidor de la protea-)Tj
T*
0.1128 Tw
[(sa, abacavir)54.9(. Abacavir es una inhibidor de la trans-)]TJ
T*
0.0018 Tw
(criptasa inversa anlogo de nuclesido, pero no inhi-)Tj
T*
0 Tw
(bidor de la proteasa.)Tj
0.9767 -1.1818 TD
0.0141 Tc
0.1109 Tw
(Posteriormente se indica que el tratamiento fue)Tj
-0.9767 -1.1818 TD
0 Tc
0.1132 Tw
(cambiando y que se combinaron diversos frmacos)Tj
T*
0.0027 Tc
0.1223 Tw
(de la misma familia, como efavirenz, estavudina y)Tj
T*
-0.0001 Tc
0 Tw
[(ritonavir)54.8(.)]TJ
0.9767 -1.1818 TD
0 Tc
0.0332 Tw
(Efavirenz es un frmaco inhibidor de la transcrip-)Tj
-0.9767 -1.1818 TD
0.0176 Tw
(tasa inversa no anlogo de nuclesido, estavudina es)Tj
T*
0.0025 Tc
0.1225 Tw
(un inhibidor de la transcriptasa inversa anlogo de)Tj
T*
0 Tc
0 Tw
(nuclesido y ritonavir es un inhibidor de la proteasa.)Tj
0.9767 -1.1818 TD
0.0609 Tw
(Resumiendo, el paciente del caso ha recibido fr-)Tj
-0.9767 -1.1818 TD
-0.0001 Tc
0.1014 Tw
(macos de las tres familias principales de antirretro-)Tj
T*
0 Tc
0.0163 Tw
(virales, inhibidores de la transcriptasa inversa anlo-)Tj
23.4616 30.7273 TD
0.0949 Tw
(gos de nuclesido y no anlogos de nuclesido, as)Tj
0 -1.1818 TD
0 Tw
(como inhibidores de la proteasa.)Tj
0.9767 -1.1818 TD
0.0051 Tc
0.1199 Tw
(Aunque los tratamientos antirretrovirales no son)Tj
-0.9767 -1.1818 TD
0 Tc
0.002 Tw
(estrategias que realice el onclogo mdico, dado que)Tj
T*
0.0016 Tc
0.1233 Tw
(la revista de Oncologa es leda por diversos espe-)Tj
T*
0.0243 Tc
0.1007 Tw
(cialistas, muchos de ellos jvenes, pienso que el)Tj
T*
0 Tc
0.0261 Tw
(aclarar estos aspectos del tratamiento, que para nada)Tj
T*
0.0907 Tw
(hacen desmerecer la calidad del trabajo presentado,)Tj
T*
0 Tw
(puede resultar interesante.)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
11 0 0 11 429.4372 384.9843 Tm
0 0 0 1 k
/GS1 gs
-0.0918 Tc
0 Tw
(F.)Tj
0.7691 0 TD
-0.0001 Tc
0.0001 Tw
[( Mar)17.7(cos Snchez)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F3 1 Tf
11 0 0 11 385.7837 371.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(Servicio de Medicina Interna.)Tj
1.8049 -1.1818 TD
(Hospital N S del Prado.)Tj
-1.624 -1.1818 TD
(T)Tj
0.4641 0 TD
[(alavera de la Reina. T)91.8(oledo.)]TJ
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
14 0 0 14 284.8479 306.9843 Tm
0 0 0 1 k
/GS1 gs
0 Tc
0 Tw
(Bibliografa)Tj
ET
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F1 1 Tf
9 0 0 9 284.8479 283.231 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0.1175 Tw
[(1.)-683.9(Andreu Martnez FJ, Martnez Mateu JM. Sarcoma de Ka-)]TJ
1.4338 -1.1948 TD
0 Tc
0.0331 Tw
(posi epidmico mucoso: aportacin de un caso y revisin de)Tj
T*
0 Tw
(la literatura. Oncologa 2005; 28: 239-243.)Tj
8.6027 -5.4961 TD
(Correspondencia:)Tj
0 -1.1948 TD
-0.0001 Tc
(Dr. F. Marcos Snchez)Tj
T*
0.0001 Tw
(C/ Gregorio Corrochano, 1)Tj
T*
0 Tc
0 Tw
(E-45600 Talavera de la Reina \(Toledo\))Tj
ET
0 0 0 0 k
26.77 788 490.35 -56 re
f
26.77 691.61 490.35 -33.61 re
f
BT
12 0 0 12 26.7705 683.4002 Tm
0 0 0 1 k
-0.0001 Tc
(Cartas al Director)Tj
ET
0 0 0 0 k
26.77 620.74 490.35 -57.66 re
f
Q
q
1 i
0 822 541 -822 re
0 822 m
W n
0.015 822.015 540.99 -822 re
W n
BT
/F2 1 Tf
16 0 0 16 26.7705 609.7988 Tm
0 0 0 1 k
/GS1 gs
-0.0001 Tc
0 Tw
[(Sar)17.7(coma de Kaposi y tratamiento antirr)17.7(etr)17.7(oviral)]TJ
ET
0 0 0 1 K
0 J 0 j 0.5 w 10 M []0 d
420.2 237.34 m
517.12 237.34 l
S
Q
endstream
endobj
5 0 obj
<<
/ProcSet [/PDF /Text ]
/Font <<
/F1 6 0 R
/F2 7 0 R
/F3 8 0 R
>>
/ExtGState <<
/GS1 9 0 R
>>
>>
endobj
11 0 obj
<<
/FunctionType 0
/Domain [0 1]
/Range [0 1]
/BitsPerSample 8
/Size [256]
/Length 271
/Filter /FlateDecode
>>
stream
H
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~
endstream
endobj
9 0 obj
<<
/Type /ExtGState
/SA false
/SM 0.02
/TR /Identity
>>
endobj
6 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 12 0 R
/BaseFont /Times-Roman
/ToUnicode 13 0 R
>>
endobj
7 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 14 0 R
/BaseFont /Times-Bold
/ToUnicode 15 0 R
>>
endobj
8 0 obj
<<
/Type /Font
/Subtype /Type1
/Encoding 16 0 R
/BaseFont /Times-Italic
/ToUnicode 17 0 R
>>
endobj
12 0 obj
<<
/Type /Encoding
/Differences [ 32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero
/one/two/three/four/five/six 56/eight/nine
/colon/semicolon 65/A 67/C/D/E/F/G
/H/I/J/K/L/M 79/O/P
82/R/S/T 86/V 97/a/b/c/d
/e/f/g/h/i/j 108/l/m
/n/o/p/q/r/s/t/u
/v 120/x/y/z 225/aacute 233/eacute 237/iacute 243/oacute
]
>>
endobj
14 0 obj
<<
/Type /Encoding
/Differences [ 32/space 46/period 66/B 70/F 75/K 77/M 83/S 97/a
/b/c/d/e/f/g/h/i
108/l/m/n/o/p 114/r/s/t
118/v 121/y/z 225/aacute 237/iacute
]
>>
endobj
16 0 obj
<<
/Type /Encoding
/Differences [ 32/space 46/period 72/H/I 77/M/N 80/P 82/R
/S/T 97/a 99/c/d/e 105/i 108/l
110/n/o/p 114/r/s/t 118/v 170/ordfeminine
]
>>
endobj
13 0 obj
<<
/Filter /FlateDecode
/Length 331
>>
stream
HTRMo0Wi PXKJ=Ck;
C!
?;:@b=$f0=
8`Nxdη[